Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P487. Infliximab in moderate-to-severe ulcerative colitis: efficacy and safety in a “real life” retrospective multicenter study from southern Italy
Authors:

M. Cappello1, M. Mazza1, G. Costantino2, W. Fries2, A.C. Privitera3, M. Mastronardi4, F. Bossa5, F. Castiglione6, A. Rispo6, A. Lauria7, N. Buccianti8, R. Marasco9, P.L. Almasio1, 1Gastroenterology Section, Di.Bi.Mis, Palermo, Italy, 2Messina, Medicina Interna, Messina, Italy, 3Azienda Ospedaliera per l'Emergenza, Ospedale Cannizzaro, Catania, Italy, 4IRCSS Castella Grotte (BA), UOC Gastroenterologia ed Endoscopia Digestiva, Castellana Grotte (BA), Italy, 5Casa Sollievo della Sofferenza, Gastroenterologia, San Giovanni Rotondo (FG), Italy, 6Università Federico II, Gastroenterologia, Napoli, Italy, 7A. O. Bianchi-Melacrino-Morelli, Reggio Calabria, Gastroenterologia, Reggio Calabria, Italy, 8A. O. S. Carlo, Potenza, U.O.C. di Medicina Interna, Potenza, Italy, 9Policlinico Catanzaro, UOC Gastroenterologia, Catanzaro, Italy

P487

A Study of Optimal Screening for Latent Tuberculosis in Patients with Inflammatory Bowel Disease

Authors:

T. Al-Taweel*, M. Strohl, T. Bessissow, A. Bitton, E. Seidman, W. Afif

McGill University Health Center, Division of Gastroenterology, Montreal, Canada

P488.

Exposure–response relationship of vedolizumab after 6 weeks of treatment in adults with Crohn's disease

Authors:

M. Rosario1, J. French2, N. Dirks2, A. Milton1, I. Fox1, M. Gastonguay2, 1Takeda Pharmaceuticals International Company, Clinical Pharmacology, Cambridge, United States, 2Metrum Research Group LLC, Biotechnology, Tariffville, United States

P488. Impact of complementary and alternative medicine on quality of life in IBD patients
Authors:

S. Nahon1, P. Lahmek2, A. Buisson3, A. Olympie4, C. Poupardin5, S. Chaussade6, B. Lesgourgues5, V. Abitbol6, 1Groupe Hospitalier Le Raincy-Montfermeil, Gastroenterology, Montfermeil, France, 2Hôpital Emile Roux, France, 3Association François Aupetit, Paris, France, 4Association François Aupetit, France, 5GHI Montfermeil, France, 6Hôpital Cochin, Gastroenterology, France

P488

Virus associated hemophagocytic syndrome: rare but serious complication of azathioprine treatment in patients with Crohn´ s disease

Authors:

J. Brezina*, L. Bajer, P. Wohl, J. Spicak, P. Drastich

Instutute of clinical and experimental medicine, Hepatogastroenterology, Prague, Czech Republic

P489.

Exposure–response relationship during vedolizumab induction therapy in adults with ulcerative colitis

Authors:

M. Rosario1, J. French2, N. Dirks2, A. Milton1, I. Fox1, M. Gastonguay2, 1Takeda Pharmaceuticals International Company, Clinical Pharmacology, Cambridge, United States, 2Metrum Research Group LLC, Biotechnology, Tariffville, United States

P489. How often is dose escalation needed in patients with inflammatory bowel disease treated with anti-TNF?
Authors:

N. Viazis1, T. Koukouratos1, E. Saprikis1, M. Al-Odat1, E. Anastasopoulos1, G. Zacharakis1, D. Karamanolis1, 1Evangelismos Hospital, 2nd Department of Gastroenterology, Athens, Greece

P489

Faecal microbiota transplantation via nasogastric route for the treatment of recurrent and antibiotic refractory Clostridum Difficile infection: The UK experience

Authors:

M.N. Quraishi*1, V. McCune2, T.H. Iqbal1, S. Pathmakanthan1, J.K. Struthers2, E. Moran2, M. Widlak1, N. Sharma2, P.M. Hawkey2

1University Hospitals Birmingham NHS Foundation Trust, Department of Gastroenterology, Birmingham, United Kingdom, 2Heart of England NHS Foundation Trust, Heartlands Hospital, Birmingham, United Kingdom

P490.

Evolution of the first-line biologic treatment and cost derived from biologic therapy from year 2000: Results of the Biologic Therapies Unit (BTU) at Hospital Universitario de La Princesa

Authors:

J.P. Gisbert1, M. Arredondo2, M. Chaparro1, I. Cañamares2, E. Daudén3, G. Fernández-Jiménez4, V. Meca5, A. Morell2, L. Carmona6, J.M. Alvaro-Gracia7, 1Hospital Universitario de La Princesa, IP and CIBERehd, Gastroenterology Unit, Madrid, Spain, 2Hospital Universitario de La Princesa and IP, Farmacy Unit, Madrid, Spain, 3Hospital Universitario de La Princesa and IP, Dermatology Unit, Madrid, Spain, 4Hospital Universitario de La Princesa and IP, Documentation Unit, Madrid, Spain, 5Hospital Universitario de La Princesa and IP, Neurology Unit, Madrid, Spain, 6Institute for Musculoskeletal Health, Madrid, Spain, 7Hospital Universitario de La Princesa and IP, Rheumatology Unit, Madrid, Spain

P490. How are thiopurines dosed in Crohn's disease? A novel strategy, maximum dose-titration based on the lower limit of leukocyte count and tolerability
Authors:

W. Moon1, T.O. Kim2, S.J. Park1, M.I. Park1, H.H. Kim1, 1Kosin University, Department of Internal Medicine, Busan, South Korea, 2Inje University, Department of Internal Medicine, Busan, South Korea

P490

Comparative analysis of the cost of maintenance treatment of Ulcerative Colitis with different compound preparation of mesalazine

Authors:

E. Hinojosa1, M. Aguas2, J. Huguet3, L. Oltra1, L. Puchades2, A. Monzó3, L. Larrey3, M. Mora1, J. Clofent4, P. Nos2, J. Hinojosa*1

1Hospital Manises, Gastroenterology, Valencia, Spain, 2Hospital Universitario i Politecnic La Fe, Gastroenterology, Valencia, Spain, 3Hospital General Universitario, Gastroenterology, Valencia, Spain, 4Hospital de Sagunto, Gastroenterology, Valencia, Spain

P491.

Epidemiology and clinical features of bloodstream infections in patients with inflammatory bowel disease

Authors:

N. Inagaki1, R. Kunisaki2, T. Sasaki2, R. Koh2, H. Kimura2, R. Wu3, K. Yaguchi4, Y. Iizuka3, K. Kobayashi3, S. Yagi3, A. Ookawara5, E. Miyajima5, M. Ohba6, H. Ohge7,8, S. Maeda9, 1Yokohama City University Medical Centre, Inflammatory bowel disease centre, Yokohama, Japan, 2Yokohama City University Medical Centre, Inflammatory Bowel Disease Centre, Yokohama, Japan, 3Yokohama City University, School of Medicine, Yokohama, Japan, 4Yokohama Cit University, School of Medicine, Yokohama, Japan, 5Yokohama City University Medical Centre, Department of Laboratory Medicine and Clinical Investigation, Yokohama, Japan, 6Yokohama City University Medical Centre, Department of Biostatistics and Epidemiology, Graduate school of Medicine, Yokohama, Japan, 7Hiroshima University, Department of Surgery, Applied Life Sciences Institute of Biomedical & Health Sciences, Hiroshima, Japan, 8Hiroshima University, Department of Infectious Diseases, Hiroshima, Japan, 9Yokohama City University Graduate School of Medicine, Department of Gastroenterology, Yokohama, Japan

P491. How are common treatment issues in patients with anti-TNF therapy addressed in real life? Results from a survey among Swiss gastroenterologists
Authors:

L. Biedermann1, S. Radivojevic2, A. Schoepfer3, G. Rogler1, S. Vavricka2, 1University Hospital Zurich, Division of Gastroenterology & Hepatology, Zurich, Switzerland, 2Triemli Hospital, Division of Gastroenterology & Hepatology, Zurich, Switzerland, 3University Hospital Lausanne, Division of Gastroenterology & Hepatology, Lausanne, Switzerland

P491

"Now I know I'm not alone": Participating in a disease-specific summer camp improves the quality of life of young people with Inflammatory Bowel Disease

Authors:

S. Lönnfors1, A. McCombie*2

1European Federation of Crohn's and Ulcerative Colitis Associations, Medical Writing, Brussels, Belgium, 2University of Otago, Medicine, Christchurch, New Zealand

P492.

Endoscopic follow up of patients with IBD and biological treatment: achievement and persistence of mucosal healing in patients with clinical remission

Authors:

R. Vadan1, L. Gheorghe1, M. Diculescu1, R. Iacob1, I. Bancila1, B. Cotruta1, N. Zamfirescu1, I. Stanel1, M. Greere1, B. Mateescu2, C. Gheorghe1, 1Fundeni Clinical Institute, Digestive Diseases and Liver Transplantation Center, Bucharest, Romania, 2Colentina Clinical Hospital, Gastroenterology, Bucharest, Romania

P492. Impact of anti-TNFa therapy of inflammatory bowel disease during pregnancy on long-term outcome of exposed children
Authors:

N. Machkova1, D. Duricova1, M. Bortlik1, K. Mitrova2, M. Durilova2, J. Bronsky2, L. Hrdlicka1, M. Lukas1, 1Charles University, IBD Clinical and Research Centre, Iscare, Prague, Czech Republic, 2Charles University, Department of Paediatrics, 2nd Faculty of Medicine, University Hospital Motol, Prague, Czech Republic

P492

Resolution of factor XI (FXI) deficiency in refractory Ulcerative Colitis (UC) after surgery: A case report

Authors:

A. Angelakopoulou1, M. Mathias2, A. Windsor3, S. McCartney4, F. Kiparissi*1, 4

1Great Ormond Street Hospital, Paediatric Gastroenterology, London, United Kingdom, 2Great Ormond Street Hospital, Haematology, London, United Kingdom, 3University College London Hospitals NHS Foundation Trust, Department of Colorectal Surgery, London, United Kingdom, 4University College London Hospitals NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom

P493.

Endoscopic balloon dilatation in patients with Crohn's disease (CD): Long-term outcome and patient satisfaction

Authors:

A. Rueda Guzman1, A. Naumann2, N.P. Malek1, M. Goetz1, 1University Hospital Tübingen, 1Department of Gastroenterology, Hepatology, and Infectiology, Medical Clinic, Tübingen, Germany, 2University Tübingen, Institute for Clinical Epidemiology and Applied Biometry, Tübingen, Germany

P493. Factors affecting adalimumab pharmacokinetics in adult patients with moderate to severe CD
Authors:

P. Noertersheuser1, D. Eckert1, S. Sharma2, R. Thakkar2, A. Robinson2, W. Sandborn3, S. Hanauer4, J.-F. Colombel5, W. Awni2, 1Abbott Laboratories, Germany, 2Abbott Laboratories, United States, 3University of California, San Diego, United States, 4University of Chicago, United States, 5Centre Hospitalier Universitaire de Lille, Hôpital Claude Huriez, Lille, France

P493

Adding 5-Aminosalicylate to Immunomodulators Showed No Additional Benefit in Crohn's Disease

Authors:

K.-J. Kim*, M.S. Kwak, J.S. Soh, D.-H. Cho, S.H. Park, J.-S. Byeon, B.D. Ye, S.-J. Myung, D.-H. Yang, S.-K. Yang, J.H. Kim

University of Ulsan College of Medicine, Gastroenterology, Seoul, South Korea